<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973723</url>
  </required_header>
  <id_info>
    <org_study_id>CG11133</org_study_id>
    <nct_id>NCT03973723</nct_id>
  </id_info>
  <brief_title>Plasma EBV DNA Monitoring in Post-treatment NPC Patients</brief_title>
  <official_title>Long-term Results of Plasma Epstein-Barr Virus DNA Monitoring In Nasopharyngeal Carcinoma After Curative Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Continuous regular monitoring of plasma EBV DNA in nasopharyngeal carcinoma (NPC) after
      treatment have rarely been investigated. The investigators try to analyze the long-term
      observational results (role in early relapse detection and impact on survival) in NPC
      patients after curative treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators enrolled 441 NPC patients who had finished finished curative radiotherapy
      with/without chemotherapy and no recurrence/metastasis before entry this study from five
      hospitals in Taiwan. Blood samples were collected on the day of enrollment and monitored once
      every 2-3 months for plasma EBV DNA measurement. After long-term observation, we analyze the
      impact of continuous plasma EBV DNA monitoring on the early dection of tumor relapse and do
      risk grouping for survival analyses according to the blood test results.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2011</start_date>
  <completion_date type="Actual">April 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time interval from the date of abnormal blood test to the date of clinically documented tumor relapse</measure>
    <time_frame>Five years</time_frame>
    <description>From the end of treatment to any time when abnormal blood test is fund</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Five years</time_frame>
    <description>Overall survival was calculated from the day of enrollment until death or the last follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>Five years</time_frame>
    <description>Event-free survival was calculated from the day of enrollment until the date of first occurrence of tumor relapse (local, regional, or distant failures) or the last follow-up visit</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">441</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>NPC</condition>
  <condition>EBV</condition>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Patients with NPC after treatment</arm_group_label>
    <description>All patients with NPC without distant metastases who receiving adequate RT dose</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and check plasma EBV DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patients with NPC who were treated at 5 hospitals (Taichung Veterans General Hospital,
        Taichung; Yuan's General Hospital, Kaohsiung; National Cheng Kung University Hospital,
        Tainan; Kaohsiung Medical University Hospital, Kaohsiung; Taipei Medical University
        Hospital, Taipei; Taiwan)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

          -  histologically-proven nasopharyngeal carcinoma without distant metastasis (M0) at
             initial presentation

          -  finished curative radiotherapy (with/without chemotherapy) within 3 years

        Exclusion criteria

          -  no occurrence of documented recurrence/metastasis before entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Ching Lin, M.D.,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Lee AW, Poon YF, Foo W, Law SC, Cheung FK, Chan DK, Tung SY, Thaw M, Ho JH. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992;23(2):261-70.</citation>
    <PMID>1587745</PMID>
  </reference>
  <reference>
    <citation>Jiong L, Berrino F, Coebergh JW. Variation in survival for adults with nasopharyngeal cancer in Europe, 1978-1989. EUROCARE Working Group. Eur J Cancer. 1998 Dec;34(14 Spec No):2162-6.</citation>
    <PMID>10070282</PMID>
  </reference>
  <reference>
    <citation>Lin JC, Jan JS, Hsu CY, Jiang RS, Wang WY. Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates. Br J Cancer. 2003 Jan 27;88(2):187-94. Review.</citation>
    <PMID>12610501</PMID>
  </reference>
  <reference>
    <citation>Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003 Feb 15;21(4):631-7.</citation>
    <PMID>12586799</PMID>
  </reference>
  <reference>
    <citation>Lin JC, Jan JS, Chen KY, Hsu CY, Liang WM, Wang WY. Outpatient weekly 24-hour infusional adjuvant chemotherapy of cisplatin, 5-fluorouracil, and leucovorin for high-risk nasopharyngeal carcinoma. Head Neck. 2003 Jun;25(6):438-50.</citation>
    <PMID>12784235</PMID>
  </reference>
  <reference>
    <citation>Chan AT, Teo PM, Leung TW, Leung SF, Lee WY, Yeo W, Choi PH, Johnson PJ. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):569-77.</citation>
    <PMID>7558945</PMID>
  </reference>
  <reference>
    <citation>Cheng SH, Jian JJ, Tsai SY, Chan KY, Yen LK, Chu NM, Tan TD, Tsou MH, Huang AT. Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 1998 Jul 1;41(4):755-62.</citation>
    <PMID>9652835</PMID>
  </reference>
  <reference>
    <citation>International Nasopharynx Cancer Study Group; VUMCA I Trial. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(&gt; or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):463-9.</citation>
    <PMID>8655368</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>NPC</keyword>
  <keyword>EBV</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Plasma Epstein-Barr virus DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

